中国P站

Biomarkers; Precision Medicine; Liquid Biopsy; Alzheimer's Disease; Cardiovascular Disease; Cancer Management; Proteomics; Metabolomics; Artificial Intelligence; Disease Diagnosis

Introduction

Biomarkers are reshaping modern medicine, offering innovative strategies for disease detection, monitoring, and treatment across various conditions. In oncology, for instance, liquid biopsies, specifically those examining circulating tumor cells (CTCs) and cell-free DNA (cfDNA), represent a significant advancement. This non-invasive approach provides a way to identify biomarkers, track disease progression, and predict how patients will respond to treatment, thereby pushing precision oncology forward considerably[1].

Beyond cancer, early and accurate diagnosis of neurological disorders such as Alzheimer's disease is paramount. Research indicates that plasma phosphorylated tau 217 (p-tau217) serves as a highly accurate blood-based biomarker for diagnosing Alzheimer's and even mild cognitive impairment, simplifying diagnostic processes and making them more accessible[2].

The field of cardiovascular disease is also experiencing rapid transformation with the discovery of new biomarkers. Reviews explore various emerging markers, ranging from genetic to proteomic, highlighting their potential to improve risk assessment and treatment strategies, leading to more personalized patient care[3].

In pediatric critical care, differentiating between bacterial and viral infections poses a substantial challenge. Studies show that host biomarkers offer promising solutions, assisting in faster and more accurate diagnosis, which enables more appropriate and timely treatment and lessens the impact of severe infections in children[4].

The broader application of biomarkers is fundamental to precision medicine, where treatments are tailored to individual patients. A systematic review confirms the clinical utility of diverse biomarkers in optimizing drug selection, dosage, and patient stratification across different diseases, moving healthcare toward more individualized approaches[5].

More specifically in cancer, circulating tumor DNA (ctDNA) is proving to be a powerful non-invasive biomarker. It aids in various aspects of cancer management, from early detection and monitoring recurrence to guiding therapy. This emphasizes its potential to revolutionize personalized cancer care and surveillance[6].

Exosomes, tiny extracellular vesicles carrying rich molecular information, are also emerging as crucial novel biomarkers. They play a significant role in disease diagnosis and prognosis across a spectrum of conditions, underlining their promise for non-invasive liquid biopsy and early detection strategies[7].

Metabolomics, which studies small molecule metabolites, provides a comprehensive overview of an organism's physiological state. This discipline is increasingly powerful in uncovering new biomarkers for diverse human diseases, from metabolic disorders to cancer, allowing for earlier detection and a deeper understanding of disease mechanisms[8].

Similarly, proteomics, the large-scale study of proteins, is an essential tool for discovering and validating clinical biomarkers. It tracks the entire process from initial hypothesis to clinical application, showing how proteomics contributes to identifying diagnostic, prognostic, and predictive markers, effectively bridging basic research with patient care[9].

Driving many of these advancements is the integration of Artificial Intelligence (AI) and Machine Learning (ML). These technologies are revolutionizing biomarker discovery by processing complex biological data to identify subtle patterns. AI tools accelerate the identification, validation, and clinical translation of biomarkers, leading to more efficient and accurate diagnostic and prognostic strategies[10].

Description

Biomarkers are fundamental to modern healthcare, providing critical insights into disease states, progression, and treatment responses. The landscape of medical diagnostics is rapidly evolving, moving towards less invasive and more precise methods. Liquid biopsies, for example, have become transformative in oncology. By analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA), clinicians can detect cancer, monitor its progression, and predict treatment efficacy without invasive procedures. This approach significantly advances precision oncology, offering a new frontier for personalized cancer management [1]. Circulating tumor DNA (ctDNA) specifically stands out as a powerful non-invasive biomarker for various aspects of cancer, from early detection and recurrence monitoring to guiding therapeutic decisions. It holds immense potential to reshape personalized cancer care and surveillance strategies [6].

The impact of biomarkers extends beyond cancer. In neurological health, early diagnosis of conditions like Alzheimer's disease is crucial. Research points to plasma phosphorylated tau 217 (p-tau217) as a highly accurate blood-based biomarker for Alzheimer's and mild cognitive impairment. This can simplify diagnostic processes, making them more accessible and timely [2]. Similarly, cardiovascular disease diagnosis and prognosis are seeing rapid advancements with the discovery of new markers. These include genetic and proteomic indicators that promise to refine risk assessment and treatment plans, leading to more individualized patient care [3].

In the realm of infectious diseases, particularly in critically ill children, distinguishing between bacterial and viral infections presents a persistent challenge. Host biomarkers offer a promising solution, facilitating faster and more accurate diagnoses. This, in turn, allows for more appropriate and timely treatment, reducing the severe impact of infections [4]. Beyond specific disease categories, biomarkers are central to the broader concept of precision medicine. A systematic review confirms their clinical utility in tailoring treatments, optimizing drug selection, dosage, and patient stratification across diverse diseases, driving healthcare towards truly individualized approaches [5].

The discovery and validation of these crucial biomarkers rely heavily on advanced technologies. Exosomes, tiny extracellular vesicles packed with molecular information, are promising candidates for novel biomarkers. Their role in disease diagnosis and prognosis across various conditions highlights their potential for non-invasive liquid biopsy and early detection strategies [7]. Metabolomics, the study of small molecule metabolites, offers a comprehensive snapshot of an organism's physiological state. It's becoming increasingly powerful for discovering new biomarkers across many human diseases, from metabolic disorders to cancer, enabling earlier detection and deeper insights into disease mechanisms [8].

Proteomics, which involves the large-scale study of proteins, is another vital tool for finding and validating clinical biomarkers. This field traces the journey from initial hypothesis to clinical application, demonstrating how it contributes to identifying diagnostic, prognostic, and predictive markers, effectively bridging basic research with direct patient care [9]. Moreover, Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing biomarker discovery. These technologies sift through complex biological data to identify subtle patterns, accelerating the identification, validation, and clinical translation of biomarkers. This promises more efficient and accurate diagnostic and prognostic strategies for the future of medicine [10].

Conclusion

Biomarkers are transforming modern medicine by offering precise tools for disease diagnosis, prognosis, and treatment monitoring. In cancer care, liquid biopsies, including circulating tumor cells (CTCs) and cell-free DNA (cfDNA), along with circulating tumor DNA (ctDNA), enable non-invasive detection, recurrence tracking, and personalized therapy. For neurological conditions, plasma phosphorylated tau 217 (p-tau217) shows high accuracy for early Alzheimer's disease diagnosis. Cardiovascular disease and infectious diseases also benefit from emerging genetic, proteomic, and host biomarkers for improved risk assessment and faster, more accurate diagnoses. Precision medicine relies on these biomarkers to tailor drug selection, dosage, and patient stratification across various conditions. The discovery and validation of these markers are significantly advanced by technologies like metabolomics, proteomics, exosomes, and the accelerating power of Artificial Intelligence (AI) and Machine Learning (ML). These innovations collectively enhance early detection, deepen understanding of disease mechanisms, and improve patient outcomes.

References

1. Emmanuel SA, Nikolaos ET, Antonios GK (2020) .J Clin Oncol 38:1421-1430.

   , ,

2. Malia RJ, Oskar S, Daniel M (2020) .Nat Med 26:397-405.

   , ,

3. Ruochen C, Mengping W, Jun Z (2023) .J Transl Med 21:190.

   , ,

4. Shin HLT, Wan MAWY, Abdullah QSA (2022) .Front Pediatr 10:951561.

   , ,

5. Jin IK, Yong K, Hong YL (2021) .J Pers Med 11:995.

   , ,

6. Yifei S, Jing Y, Min H (2023) .Cancers (Basel) 15:807.

   , ,

7. Hongbo W, Yong L, Yue F (2021) .J Mol Med (Berl) 99:735-752.

   , ,

8. Zhaoli Z, Bao GF, Xiao HY (2021) .Metabolites 11:729.

   , ,

9. Min FZ, Yu LZ, Shan L (2020) .Expert Rev Proteomics 17:429-440.

   , ,

10. Yujie L, Jun W, Jianli X (2022) .Med Res Rev 42:1438-1466.

    , ,